ACAD: ACADIA Corp PEG Multiple
Competent management at ACADIA Pharmaceuticals (ACAD) ensures transparency in clinical trials and effective patent protection. The GURU.Markets system provides the peg level dynamics, where the current level is approximately 0.00. Premium pricing for unique Parkinson's disease medications guarantees high margins. Business stability is supported by in-house production in the US and strong leadership in narrow neurobiological niches.
ACADIA Pharmaceuticals (ACAD) - metric breakdowns and financial figures
- market price and analyst price targets:
- market capitalization information:
- balance sheet equity data:
- debt obligations and liquidity statistics:
Total Debt to Capital ACADIA Pharmaceuticals|ACAD - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital acadia-pharm.com|ACAD - Company Debts|Debts to Book Capitalization Ratio ACADIA Pharmaceuticals Inc|ACAD - Company Long-Term Debts|Company Short-Term Loans and Borrowings ACADIA Pharmaceuticals|Quick Ratio acadia-pharm.com
- net income and valuation multiples indicators:
ACAD - Company Net Income|Expected Net Income ACADIA Pharmaceuticals|ACAD - Price to Earnings Ratio|Projected Price to Earnings ACADIA Corp|ACAD - PEG Multiple|EV/EBITDA Multiple ACADIA Pharmaceuticals Inc|ACAD - Operating profit EBITDA|Net earnings per share for the last 12 months ACADIA Pharmaceuticals|ACAD - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months acadia-pharm.com|ACAD - Net earnings per share growth this year|Earnings growth forecast for next year ACADIA Pharmaceuticals
Fundamental company analysis:ACADIA Pharma - ACAD
The reliability of ACADIA Pharmaceuticals (ACAD) neurological drug supply chains provides a stable foundation for analyzing the normalized PEG ratio. The current value of 0.00 reflects the P/E ratio relative to earnings growth rates, where a figure below one signals an undervaluation of the business relative to its expansion, allowing investors to identify the asset's growth potential provided fiscal risks are controlled.
Competing companies
Price/Earnings to Growth Multiple Biogen Inc BIIB|PEG Multiple NBIX (Neurocrine Biosciences Inc)|PEG Multiple Regencell Corp RGC|Axsome Therapeutics - PEG Multiple|XENE (xenon-pharma.com) - Growth-Adjusted P/E Ratio|VKTX: PEG Multiple|SUPN - Growth-Adjusted Market Cap to Net Income|CPRX (Catalyst Pharmaceuticals Inc) - PEG Multiple|PEG Multiple Denali Corp|Price/Earnings to Growth Multiple HRMY (Harmony Biosciences)|BHVN (biohavenpharma.com) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Amylyx Pharmaceuticals, Inc. AMLX|TRVI (Trevi Therapeutics Inc) - Market Cap to Earnings and Growth Ratio|Praxis Medicines - PEG Multiple|Growth-Adjusted Payback Ratio AVXL (Anavex Life Sciences Corp)|CBLL: PEG Multiple|Prothena (PRTA) - PEG Multiple|Price/Earnings to Growth Ratio Alector Inc.|ANNX: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Omeros Corporation (OMER)|Price/Earnings to Growth Multiple Neurogene Therapeutics NGNE|PEG Multiple ACIU (AC Immune)|PEG Multiple voyagertherapeutics.com VYGR|Neumora Therapeutics, Inc. - PEG Multiple|Scilex Holding (SCLX) - Price/Earnings to Growth Multiple|TVGN: PEG Multiple|Price to Earnings Adjusted for Growth Rate Alpha Cognition Inc. (ACOG)|Price/Earnings to Growth Multiple CGTX|PEG Multiple inhibikase.com|Price/Earnings to Growth Multiple SAVA (Cassava Sciences)|Company Value to Earnings Growth Ratio ASRT|PEG Multiple COYA (Coya Therapeutics)|Growth-Adjusted Market Cap to Net Income VistaGen Therapeutics, Inc. (VTGN)|Ovid Rx - PEG Multiple|acumenpharm.com (ABOS) - Price/Earnings to Growth Multiple|CRVO: PEG Multiple|Alterity Therapeutics Limited (ATHE) - PEG Multiple|Price/Earnings to Growth Ratio Clene Inc|Price/Earnings to Growth Ratio PEPG|Price/Earnings to Growth Ratio Jupiter Neurosciences Inc (JUNS)|Growth-Adjusted Market Cap to Net Income relmada.com|PEG Multiple ANVS (Annovis Bio)|PEG Multiple Grace Therapeutics Inc GRCE|Firefly Neuroscience Inc - PEG Multiple|Klotho Neurosciences Inc (KLTO) - Price/Earnings to Growth Multiple|NRSN: PEG Multiple|revivapharma.com (RVPH) - PEG Multiple|MTVA (MetaVia Inc.) - PEG Multiple|Growth-Adjusted P/E Ratio NRXS (NeurAxis Inc.)|Price/Earnings to Growth Ratio Helius Medical (HSDT)|passagebio.com - Growth-Adjusted P/E Ratio|PEG Multiple NEUP (Neuphoria Therapeutics)|minervaneurosciences.com (NERV) - Price to Earnings Adjusted for Growth Rate|ATHA: Price/Earnings to Growth Multiple|ADXN - PEG Multiple|alzamend.com (ALZN) - Price/Earnings to Growth Ratio|Cyclerion Therapeutics, Inc. - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Protagenic Therapeutics Inc.|Price to Earnings Adjusted for Growth Rate Pasithea KTTA|PEG Multiple CRGT|PEG Multiple Avenue Therapeutics Inc. (ATXI)|PEG Multiple BCLI (Brainstorm Cell Therapeutics, Inc.)|CARA - Price/Earnings to Growth Multiple|Chromocell Therapeutics - PEG Multiple|ELYM - PEG Multiple|ITCI: PEG Multiple|Growth-Adjusted P/E Ratio LBPH|MRNS (Marinus) - PEG Multiple|NKGen Biotech Corp (NKGN) - Growth-Adjusted Market Cap to Net Income|PEG Multiple NRBO|PEG Multiple sagerx.com (SAGE)|Synaptogenix - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio TRVN|VIGL - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio WENA|CERE: PEG Multiple
